Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 42 citing articles:

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 68
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vráblík
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
Piero Portincasa, György Baffy
European Journal of Internal Medicine (2024) Vol. 124, pp. 35-39
Open Access | Times Cited: 10
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2024) Vol. 157, pp. 155936-155936
Closed Access | Times Cited: 9
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
Qiong Lv, Hua-Shan Zhao
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 8
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
Niki Katsiki, Theodosios D. Filippatos, Charalambos Vlachopoulos, et al.
Atherosclerosis Plus (2024) Vol. 55, pp. 74-92
Open Access | Times Cited: 8
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 8
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery
Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki, et al.
Metabolism (2023) Vol. 148, pp. 155689-155689
Open Access | Times Cited: 19
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Matina Kouvari, et al.
Metabolism (2023) Vol. 148, pp. 155694-155694
Closed Access | Times Cited: 17
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 7
Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults
Jing Yan, Jun Zhou, Yuanyuan Ding, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 5
Allura Red AC is a xenobiotic. Is it also a carcinogen?
Lorne J. Hofseth, James R. Hébert, Elizabeth A. Murphy, et al.
Carcinogenesis (2024) Vol. 45, Iss. 10, pp. 711-720
Closed Access | Times Cited: 5
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao Chen, Yang Zhou, Haiping Hao, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 8, pp. 724-745
Closed Access | Times Cited: 5
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 5
Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020
Nan Luo, Xuan Zhang, Jingtao Huang, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. e70-e71
Open Access | Times Cited: 12
Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications
Lili Yu, Feifei Gao, Yaoxin Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116724-116724
Open Access | Times Cited: 4
The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 8, pp. 108780-108780
Closed Access | Times Cited: 4
Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus
Mengmeng Hu, Jingyu Yang, Beibei Gao, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Alexios Giannakodimos, Evangelos Oikonomou, Panteleimon Pantelidis, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Barış Afşar, Rengin Elsürer Afşar
Clinical Nutrition (2023) Vol. 42, Iss. 12, pp. 2338-2352
Closed Access | Times Cited: 12
From NAFLD to MASLD: When metabolic comorbidity matters
Shan Hong, Lei Sun, Yiwei Hao, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101281-101281
Open Access | Times Cited: 11
Regulated regeneration of adipose tissue in lipodystrophic Agpat2-null mice partially ameliorates hepatic steatosis
Anil K. Agarwal, Katie Tunison, Jay D. Horton, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109517-109517
Open Access | Times Cited: 3
Association of ultra-processed food intake with severe non-alcoholic fatty liver disease: a prospective study of 143073 UK Biobank participants
Yifeng Zhang, Wanning Qiao, Jinhong Zhuang, et al.
The journal of nutrition health & aging (2024) Vol. 28, Iss. 10, pp. 100352-100352
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top